Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Array Biopharma, Inc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (296)	6/2/2014 1:20:29 PM
From: scaram(o)uche	Respond to of 321

>> Meanwhile, we get no update on the cdk4/6 combo trial. << Out now, from ARRY. Language, abstract...... "As of Dec 20, 2013, 14 pts were enrolled..... Six pts achieved partial response (43%; 1 confirmed, 5 unconfirmed) and 6 had stable disease (4 with tumor shrinkage > 20%). Several pts experienced early tumor shrinkage with major symptomatic improvement; 8 pts remain on treatment (duration 2-8 mo)." Language, today's release..... "As of March 21, 2014, 22 patients were enrolled. Of 21 evaluable patients, seven achieved a partial response (33%, 3 confirmed, 4 unconfirmed) and 11 had stable disease (52%). Several patients experienced early tumor shrinkage with major symptomatic improvement; 12 patients remain on treatment (55%, duration 2 to 8 months)."